
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Algernon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program
Details : Algernon Pharmaceuticals has awarded the contract to manufacture the active pharmaceutical ingredient and finished product for its formulation of AP-188 (“N,N-Dimethyltryptamine or DMT”), to Canadian-based Dalton Pharma Services.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 19, 2021
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Algernon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : VIDO-InterVac
Deal Size : Undisclosed
Deal Type : Partnership
Dalton, VIDO-InterVac Partner to Develop COVID-19 Vax
Details : Under this Partnership, Dalton will be responsible for the formulation and fill/finish of VIDO-InterVac’s COVID-19 vaccine to be used in early Phase clinical trials from Dalton`s cGMP biopharmaceutical facility in Toronto, Canada.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 28, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : VIDO-InterVac
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Health Canada
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Dalton Expands Cannabinoids Capabilities
Details : Dalton receives the license amendment from Health Canada under Cannabis regulations enabling transfer of finished cGMP cannabis products to licensed dealers.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 15, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Health Canada
Deal Size : Undisclosed
Deal Type : Licensing Agreement
